219 related articles for article (PubMed ID: 29854980)
1. Benefit of Apabetalone on Plasma Proteins in Renal Disease.
Wasiak S; Tsujikawa LM; Halliday C; Stotz SC; Gilham D; Jahagirdar R; Kalantar-Zadeh K; Robson R; Sweeney M; Johansson JO; Wong NC; Kulikowski E
Kidney Int Rep; 2018 May; 3(3):711-721. PubMed ID: 29854980
[TBL] [Abstract][Full Text] [Related]
2. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
[TBL] [Abstract][Full Text] [Related]
3. Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment.
Gilham D; Wasiak S; Rakai BD; Fu L; Tsujikawa LM; Sarsons CD; Carestia A; Lebioda K; Johansson JO; Sweeney M; Kalantar-Zadeh K; Kulikowski E
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371758
[TBL] [Abstract][Full Text] [Related]
4. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Wasiak S; Dzobo KE; Rakai BD; Kaiser Y; Versloot M; Bahjat M; Stotz SC; Fu L; Sweeney M; Johansson JO; Wong NCW; Stroes ESG; Kroon J; Kulikowski E
Clin Epigenetics; 2020 Nov; 12(1):166. PubMed ID: 33172487
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response
Wasiak S; Gilham D; Daze E; Tsujikawa LM; Halliday C; Stotz SC; Rakai BD; Fu L; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Cardiovasc Ther; 2020; 2020():9397109. PubMed ID: 32821285
[TBL] [Abstract][Full Text] [Related]
6. Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.
Kulikowski E; Halliday C; Johansson J; Sweeney M; Lebioda K; Wong N; Haarhaus M; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Kidney Blood Press Res; 2018; 43(2):449-457. PubMed ID: 29566379
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells.
Wasiak S; Tsujikawa LM; Daze E; Gilham D; Stotz SC; Rakai BD; Sarsons CD; Fu L; Azhar S; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Atherosclerosis; 2023 Jan; 364():10-19. PubMed ID: 36455344
[TBL] [Abstract][Full Text] [Related]
8. Apabetalone downregulates factors and pathways associated with vascular calcification.
Gilham D; Tsujikawa LM; Sarsons CD; Halliday C; Wasiak S; Stotz SC; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kalantar-Zadeh K; Kulikowski E
Atherosclerosis; 2019 Jan; 280():75-84. PubMed ID: 30476723
[TBL] [Abstract][Full Text] [Related]
9. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.
Cummings J; Schwartz GG; Nicholls SJ; Khan A; Halliday C; Toth PP; Sweeney M; Johansson JO; Wong NCW; Kulikowski E; Kalantar-Zadeh K; Lebioda K; Ginsberg HN; Winblad B; Zetterberg H; Ray KK
J Alzheimers Dis; 2021; 83(4):1703-1715. PubMed ID: 34459400
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.
Fu L; Wasiak S; Tsujikawa LM; Rakai BD; Stotz SC; Wong NCW; Johansson JO; Sweeney M; Mohan CM; Khan A; Kulikowski E
Pharmacol Res Perspect; 2022 Jun; 10(3):e00949. PubMed ID: 35417091
[TBL] [Abstract][Full Text] [Related]
11. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.
Nicholls SJ; Ray KK; Johansson JO; Gordon A; Sweeney M; Halliday C; Kulikowski E; Wong N; Kim SW; Schwartz GG
Am J Cardiovasc Drugs; 2018 Apr; 18(2):109-115. PubMed ID: 29027131
[TBL] [Abstract][Full Text] [Related]
12. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
[TBL] [Abstract][Full Text] [Related]
13. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.
Haarhaus M; Ray KK; Nicholls SJ; Schwartz GG; Kulikowski E; Johansson JO; Sweeney M; Halliday C; Lebioda K; Wong N; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Atherosclerosis; 2019 Nov; 290():59-65. PubMed ID: 31568963
[TBL] [Abstract][Full Text] [Related]
14. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.
Kalantar-Zadeh K; Schwartz GG; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kulikowski E; Lebioda K; Toth PP; Wong N; Sweeney M; Ray KK;
Clin J Am Soc Nephrol; 2021 May; 16(5):705-716. PubMed ID: 33906908
[TBL] [Abstract][Full Text] [Related]
15. The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation
Wasiak S; Fu L; Daze E; Gilham D; Rakai BD; Stotz SC; Tsujikawa LM; Sarsons CD; Studer D; Rinker KD; Jahagirdar R; Wong NCW; Sweeney M; Johansson JO; Kulikowski E
Transl Neurosci; 2023 Jan; 14(1):20220332. PubMed ID: 38222824
[TBL] [Abstract][Full Text] [Related]
16. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Nicholls SJ; Schwartz GG; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Ray KK;
Cardiovasc Diabetol; 2021 Jan; 20(1):13. PubMed ID: 33413345
[TBL] [Abstract][Full Text] [Related]
17. Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes.
Brandts J; Ray KK
Future Cardiol; 2020 Sep; 16(5):385-395. PubMed ID: 32378426
[TBL] [Abstract][Full Text] [Related]
18. The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation.
Zhang XX; Lin J; Liang TZ; Duan H; Tan XH; Xi BM; Li L; Liu SW
Acta Pharmacol Sin; 2019 Jan; 40(1):98-110. PubMed ID: 29789664
[TBL] [Abstract][Full Text] [Related]
19. Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells.
Sarsons CD; Gilham D; Tsujikawa LM; Wasiak S; Fu L; Rakai BD; Stotz SC; Carestia A; Sweeney M; Kulikowski E
Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37893058
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Wasiak S; Gilham D; Tsujikawa LM; Halliday C; Calosing C; Jahagirdar R; Johansson J; Sweeney M; Wong NC; Kulikowski E
J Cardiovasc Transl Res; 2017 Aug; 10(4):337-347. PubMed ID: 28567671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
